Hydreight Technologies Achieves Remarkable Growth and Recognition

Hydreight Technologies Reports Exceptional Corporate Updates
Exciting developments are unfolding as Hydreight Technologies continues to enhance its telehealth services, with over 295,000 VSDHOne product orders reported, showcasing its rapid expansion and a robust cash reserve of approximately CA$18.7 million.
Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS | OTCQB: HYDTF | FSE: SO6) has shared a corporate update, emphasizing its notable advancements and recognitions that underline its impact on the healthcare technology landscape.
Among its recent accolades, Hydreight has proudly secured the #25 position on Deloitte’s 2025 Technology Fast 50™, reflecting impressive revenue growth from 2021 to 2024. Previously, the Company earned the #56 rank on Deloitte’s 2024 Technology Fast 500™ (U.S.). This recognition signifies Hydreight's commitment to innovation and excellence across North America.
Industry Accolades and Recognition
These acknowledgments reflect the accolades Hydreight has received:
- Top 50 TSX Venture Exchange Company for 2024.
- Finalist for the Company of the Year – Scale Award at the BC Tech Association’s 2025 Technology Impact Awards (TIAs).
- Pacific Region finalist for the EY Entrepreneur of the Year Canada 2025 Awards.
These achievements reinforce Hydreight’s advancement in modernizing healthcare delivery through technology, compliance, and nationwide scalability.
Strengthening Telehealth Infrastructure
Hydreight boasts one of the country’s largest compliant telehealth networks, linking healthcare providers, pharmacies, and patients via its proprietary VSDHOne platform across all 50 states.
Notable Highlights from the Company:
- Product Orders: Approximately 295,000 VSDHOne product orders processed in the recent quarter, indicating significant growth in various healthcare services such as weight management, hormone therapy, and genetic testing.
- Expansion of Nurse Network: The Company realized an increase of 49% in new nurse sign-ups, showcasing its commitment to broadening its healthcare services.
- Pharmacy Orders: A 72% year-over-year increase emphasizes the strong demand for services.
- Financial Position: With an enhanced liquidity position following an oversubscribed CA$11.5 million financing, Hydreight's cash reserves stand at approximately CA$18.7 million, enabling aggressive growth strategies.
- Technology Advancement: Integration with pharmacy partners aims to improve capacity, fulfillment speed, and margins, along with the impending launch of VSDHOne V2, offering improved automation and scalability.
- Mergers & Acquisitions (M&A) Pipeline: The Company is actively pursuing profitable wellness and digital-health operators for national scalability.
Management Insights
CEO Shane Madden shared, "Hydreight’s recognition by Deloitte as a leading technology company reflects our robust execution. The recent quarter demonstrated the scalability of our healthcare infrastructure, supported by significant financial resources, allowing for an acceleration of growth initiatives across various segments."
Future Plans and Strategic Priorities
As Hydreight navigates through the upcoming quarter of 2025, the focus remains on driving operational momentum. The Company is dedicated to furthering its GLP-1, direct-to-consumer (D2C), and pharmacy integration efforts, ensuring a profitable and compliant expansion aligned with shareholder value.
Hydreight's strategic initiatives include:
- Direct-to-Consumer (D2C): Accelerating its D2C initiatives, allowing brands to quickly gain access to the healthcare market.
- GLP-1 Program Expansion: Meeting increasing patient demand through ongoing program rollout.
- Improved Pharmacy Network Integration: Enhancing fulfillment and improving margins through deeper partnerships.
- Advancements in Technology: Promoting modular platform design that supports individualized telehealth operations and compliance.
Investor engagement continues to thrive as well, with new analyst coverage initiated by several firms, showcasing an interest in Hydreight's rapid ascent within the healthcare technology sector.
Contact Information
For more inquiries, please reach out to:
Email: ir@hydreight.com
Telephone: (702) 970-8112
Frequently Asked Questions
What recent achievements has Hydreight Technologies made?
Hydreight secured the #25 position on Deloitte’s 2025 Technology Fast 50™ for its rapid revenue growth and was recognized as a Top 50 TSX Venture Exchange Company.
How many product orders did Hydreight process recently?
The Company processed approximately 295,000 VSDHOne product orders between July and September.
What is the VSDHOne platform?
The VSDHOne platform is Hydreight’s proprietary digital healthcare solution, designed to streamline telehealth services and improve patient access to treatment.
What are the future plans of Hydreight Technologies?
Hydreight plans to expand its GLP-1 and direct-to-consumer wellness offerings while enhancing partnerships within its pharmacy network.
How can I contact Hydreight for more information?
You can reach Hydreight by emailing ir@hydreight.com or calling (702) 970-8112.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.